JNJ

167.52

-0.36%↓

NVS

117.07

-0.07%↓

ABT

128.81

+1.43%↑

TMO

478.5

-1.61%↓

ISRG

501.25

+0.6%↑

JNJ

167.52

-0.36%↓

NVS

117.07

-0.07%↓

ABT

128.81

+1.43%↑

TMO

478.5

-1.61%↓

ISRG

501.25

+0.6%↑

JNJ

167.52

-0.36%↓

NVS

117.07

-0.07%↓

ABT

128.81

+1.43%↑

TMO

478.5

-1.61%↓

ISRG

501.25

+0.6%↑

JNJ

167.52

-0.36%↓

NVS

117.07

-0.07%↓

ABT

128.81

+1.43%↑

TMO

478.5

-1.61%↓

ISRG

501.25

+0.6%↑

JNJ

167.52

-0.36%↓

NVS

117.07

-0.07%↓

ABT

128.81

+1.43%↑

TMO

478.5

-1.61%↓

ISRG

501.25

+0.6%↑

Search

Sanofi

Deschisă

49.17 -0.73

Rezumat

Modificarea prețului

24h

Curent

Minim

48.72

Maxim

49.64

Indicatori cheie

By Trading Economics

Venit

1.4B

1.9B

Vânzări

3B

11B

P/E

Medie Sector

16.887

38.156

EPS

1.022

Marjă de profit

17.65

Angajați

82,878

EBITDA

2.2B

2.8B

Recomandări

By TipRanks

Recomandări

Cumpărare

Prognoză pe 12 luni

+24.01% upside

Statistici piață

By TradingEconomics

Capitalizare de piață

-16B

122B

Deschiderea anterioară

49.9

Închiderea anterioară

49.17

Scor tehnic

By Trading Central

Încredere

Strong Bearish Evidence

Sanofi Grafic

Performanțele din trecut nu reprezintă un indicator fiabil al rezultatelor viitoare.

Știri relevante

22 iul. 2025, 12:03 UTC

Achiziții, Fuziuni, Preluări

Sanofi to Buy Vaccine Developer Vicebio for Up to $1.6 Billion -- Update

22 iul. 2025, 05:56 UTC

Achiziții, Fuziuni, Preluări

Sanofi to Buy Vaccine Developer Vicebio for Up to $1.6 Billion

1 iul. 2025, 12:03 UTC

Principalele dinamici ale pieței
Achiziții, Fuziuni, Preluări

Adagene ADRs Rise Following Sanofi Investment

11 iun. 2025, 08:25 UTC

Achiziții, Fuziuni, Preluări

EQT, Sanofi Co-Led $135 Million Funding Round for Spanish Biotech Company SpliceBio

2 iun. 2025, 16:05 UTC

Principalele dinamici ale pieței

Nurix Therapeutics Stock Climbs as Sanofi Extends License for STAT6

2 iun. 2025, 09:17 UTC

Achiziții, Fuziuni, Preluări

Sanofi to Buy Blueprint Medicines for Up to $9.5 Billion in Boost to Pipeline -- Update

2 iun. 2025, 05:31 UTC

Achiziții, Fuziuni, Preluări

Sanofi to Acquire Blueprint Medicines for Up to $9.5 Billion

22 iul. 2025, 08:45 UTC

Market Talk
Achiziții, Fuziuni, Preluări

Sanofi's Vicebio Acquisition Could Make Up for Pipeline Setbacks -- Market Talk

22 iul. 2025, 05:33 UTC

Achiziții, Fuziuni, Preluări

Sanofi: Deal Won't Have Significant Impact on Guidance for 2025

22 iul. 2025, 05:33 UTC

Achiziții, Fuziuni, Preluări

Sanofi: Transaction Is Expected to Close in 4Q

22 iul. 2025, 05:33 UTC

Achiziții, Fuziuni, Preluări

Sanofi to Buy All of Vicebio for Upfront Payment of $1.15B, Milestone Payments of Up to $450M

22 iul. 2025, 05:32 UTC

Achiziții, Fuziuni, Preluări

Sanofi: Vicebio Is Privately Held Biotechnology Company Based in London

22 iul. 2025, 05:31 UTC

Achiziții, Fuziuni, Preluări

Sanofi: Acquisition of Vicebio Seeks to Expand Respiratory Vaccines Pipeline

22 iul. 2025, 05:31 UTC

Achiziții, Fuziuni, Preluări

Sanofi to Buy Vicebio

22 iul. 2025, 05:30 UTC

Achiziții, Fuziuni, Preluări

Press Release: Sanofi To Acquire Vicebio, Expanding Respiratory Vaccines Pipeline >SAN.FR

18 iul. 2025, 05:00 UTC

Achiziții, Fuziuni, Preluări

Press Release: Sanofi Completes Acquisition Of Blueprint Medicines >SAN.FR

9 iul. 2025, 10:59 UTC

Market Talk

Pharma Companies Would Be Severely Hurt by 200% Tariff -- Market Talk

9 iul. 2025, 09:17 UTC

Acțiuni populare

Stocks to Watch Wednesday: Freeport-McMoRan, Glencore, Novo Nordisk -- WSJ

1 iul. 2025, 16:55 UTC

Câștiguri

10 European Dividend Stocks That Could Beat Their U.S. Counterparts -- Barrons.com

10 iun. 2025, 12:18 UTC

Câștiguri

Why Moderna, Pfizer Stocks Are Shrugging Off RFK Jr.'s Firing of Vaccine Advisors. -- Barrons.com

2 iun. 2025, 13:50 UTC

Câștiguri
Achiziții, Fuziuni, Preluări

Blueprint Medicines Soars 26% on $9.5 Billion Buyout. Why This Drug Is Key to the Deal. -- Barrons.com

2 iun. 2025, 12:33 UTC

Market Talk
Achiziții, Fuziuni, Preluări

Sanofi Portfolio Approach Awaits Proof of Improvement -- Market Talk

2 iun. 2025, 10:50 UTC

Achiziții, Fuziuni, Preluări

Blueprint Medicines Soars 27% on $9.5 Billion Buyout. Why This Drug Is Key to the Deal. -- Barrons.com

2 iun. 2025, 10:05 UTC

Market Talk
Achiziții, Fuziuni, Preluări

Sanofi's Blueprint Deal Seems Like Good Fit -- Market Talk

2 iun. 2025, 05:06 UTC

Achiziții, Fuziuni, Preluări

Sanofi: Total Equity Value, Including Potential CVR Payments, Represents About $9.5B on Fully Diluted Basis

2 iun. 2025, 05:06 UTC

Achiziții, Fuziuni, Preluări

Sanofi: Blueprint Shareholders Also Will Receive One Non-Tradeable Contingent Value Right

2 iun. 2025, 05:05 UTC

Achiziții, Fuziuni, Preluări

Sanofi: Deal Represents an Equity Value of Approximately $9.1B

2 iun. 2025, 05:05 UTC

Achiziții, Fuziuni, Preluări

Sanofi Will Pay $129.00 Per Share in Cash at Closing

2 iun. 2025, 05:04 UTC

Achiziții, Fuziuni, Preluări

Sanofi: Blueprint Is Expected to Enhance Sanofi's Growing Immunology Pipeline

2 iun. 2025, 05:04 UTC

Achiziții, Fuziuni, Preluări

Sanofi: Acquisition Includes Rare Immunology Disease Medicine, Ayvakit/Ayvakyt

Comparație

Modificare preț

Sanofi Așteptări

Obiectiv de preț

By TipRanks

24.01% sus

Prognoză pe 12 luni

Medie 61.2 USD  24.01%

Maxim 67 USD

Minim 56 USD

În baza a 5 analiști de pe Wall Street care oferă obiective de preț pe 12 luni pentruSanofi - Dist în ultimele 3 luni.

Consens privind evaluarea

By TipRanks

Cumpărare

5 ratings

2

Cumpărare

3

Păstrare

0

Vânzare

Scor tehnic

By Trading Central

51.665 / 52.38Suport & Rezistență

Termen scurt

Strong Bearish Evidence

Termen mediu

Weak Bullish Evidence

Termen lung

Bullish Evidence

Date financiare

Cheltuieli de vânzare și administrare

Cheltuieli de exploatare

Profit pre-impozitare

Vânzări

Costul vânzărilor

Profit brut din vânzări

Cheltuieli cu dobânzile pe datorie

EBITDA

Profit operațional

$

Despre Sanofi

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products. In addition, it offers poliomyelitis, pertussis, and hib pediatric vaccines; influenza, booster, meningitis, and travel and endemic vaccines, which includes hepatitis A, typhoid, cholera, yellow fever, and rabies vaccines. The company also provides cough, cold, and flu, allergy, and pain care products, as well as physical, mental, and digestive wellness products; and offers products for itching, hydration, aging, cracking, overnight, and specialty skincare needs like eczema. Further, it has a collaboration and license agreement with Exscientia to develop up to 15 novel small-molecule for oncology and immunology; ABL Bio, Inc. to develop ABL301, a treatment for alpha-synucleinopathies; Blackstone Life Sciences to develop pivotal studies and clinical development program; and Seagen Inc. to design, develop, and commercialize antibody-drug conjugates for cancer. Additionally, the company has a collaboration agreement with IGM Biosciences, Inc. to develop, manufacture, and commercialize IgM antibody; Skyhawk Therapeutics, Inc to discover and develop novel small molecules; and Adagene Inc., for the discovery and development of antibody-based therapies. It also has collaborations with Scribe Therapeutics Inc. to develop genome editing technologies; and co-promotion service agreement with Provention Bio, Inc. for the commercialization of teplizumab. The company was formerly known as Sanofi-Aventis and changed its name to Sanofi in May 2011. Sanofi was incorporated in 1994 and is headquartered in Paris, France.